Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Date:3/12/2009

CALGARY, March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor, Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.

"We are quite excited about this trial, since there are no known therapies that to date have effectively targeted K-RAS in cancer patients," said Dr. Villalona-Calero. "If this therapy works, this could substantially impact the outlook for our patients."

This trial (REO 016) is a single arm, single-stage, open-label, Phase 2 study of REOLYSIN(R) given intravenously with paclitaxel and carboplatin every 3 weeks. Patients will receive four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN(R), at which time REOLYSIN(R) may be continued as a monotherapy. It is anticipated that up to 36 patients will be treated in this trial.

Eligible patients include those with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, who have not received chemotherapy treatment for their metastatic or recurrent disease. Patients must have demonstrated mutations in K-RAS or EGFR, or EGFR gene amplification in their tumours (metastatic or primary) in order to qualify for the trial.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
2. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
3. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
4. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
8. AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
9. AMA Foundation Announces Seed Grant Research Recipients
10. Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
11. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , February 27, 2015 ... bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) in ...     ... ein neuartiges Herzüberwachungssystem für Patienten mit kongestiver ... dass sie ein Finanzierungsvorhaben über 5 Mio. ...
(Date:2/27/2015)... JERUSALEM , Feb. 27, 2015  Chiasma, Inc., ... lead product for the orphan condition acromegaly, today announced ... round. Participants in the financing included new investors Rock ... chip public investment fund, as well as existing investors ... and ARCH Venture Partners. Chiasma intends ...
(Date:2/26/2015)... February 27, 2015 RnRMarketResearch.com ... market research report to its store. This report ... therapeutic pipeline. The report "Corneal Ulcers - Pipeline ... therapeutic development for Corneal Ulcers. Corneal Ulcers are ... bacterial infections, viral infections & fungal infections. The ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
... Heart, Inc. today announced that NewYork-Presbyterian Hospital/ Columbia ... U.S. center, and first in the Northeast, to ... of the DuraHeart Bridge-To-Transplant U.S. pivotal trial, a ... up to 40 centers nationwide. The trial ...
... 7 NovaBay Pharmaceuticals, Inc. (NYSE Alternext: ... novel, synthetic anti-infective products for the treatment ... bacterial, fungal, and viral infections without developing ... that NVC-422, the Company,s lead Aganocide(R) compound, ...
Cached Medicine Technology:Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 2Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 3NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection 2NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection 3NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection 4
(Date:3/1/2015)... Ticket Down is a reputable source for authentic tickets ... Deadheads have been anxiously anticipating this blockbuster weekend ever since ... 50 years ago back in the 60s in Palo Alto, ... death of Jerry Garcia in 1995. This beloved group ... bluegrass, folk, space rock and country to become an unforgettable ...
(Date:3/1/2015)... Indiana Fiber Network, LLC (IFN), the ... Networking, LLC (NewWays) selected IFN as primary fiber ... is well positioned to scale future backbone transport ... in rural parts of Indiana,” said Scott Reed, ... IFN Enterprise Sales Manager, IFN provides NewWays fiber ...
(Date:3/1/2015)... 2015 “ The Barrel Mill ” was ... which takes a look at the latest and coolest technology ... of NewsWatch and a technology expert, conducted the review and ... to drinks. , According to Home Distillation of Alcohol, it's ... Well, there’s a pretty cool product that’ll help anyone achieve ...
(Date:3/1/2015)... 28, 2015 CrossFit Attollo is a CrossFit ... offering a special discount to new members. Now through ... a three month contract will receive their fourth month half ... cost members $440. The three month contract is only ... then the fourth month comes in at only $55. The ...
(Date:2/28/2015)... 2015 In recent years Medical Marijuana has ... physicians as a way for them to expand their patient ... as medicine. Since the FDA still lists Cannabis as a ... to licensed physicians that can help guide them when ... Malka in Santa Cruz, CA is a leader in ...
Breaking Medicine News(10 mins):Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2
... the lungs in bar workers according to a new study//. ... of the American Medical Association, and comes from Scotland where ... banned on March 26, 2006. ,Researchers such ... in Dundee, Scotland took this opportunity to study 77 nonsmoking ...
... of colon cancer (carcinoma) cases has been discovered by ... which could be the possible target for treatment against ... were able to rescue zebra fish from the effects ... gene, by genetically disabling (undoing) a molecule called C-Terminal ...
... "Mediterranean" diet rich in olive oil, vegetables, fruits, legumes, ... Alzheimer's disease according to U.S. researchers. ,Lead researcher ... Columbia University Medical Center in New York said, "We ... Alzheimer's disease." ,Scarmeas added that this benefit ...
... Dr Mukesh Haikerwal, said today the Government must make ... to be truly effective in meeting the needs of ... were announced today by the Prime Minister, and the ... care. ,While the AMA is generally pleased ...
... for permission with European medicine regulators to begin selling its ... move in the US last month, and comes slightly earlier ... to be one of GSK's most promising pipeline drugs as ... Code the sales of the drug could cross 2 bln ...
... under go lumpectomy feel that the outcome is a ... look, a recent survey has revealed. , ,The ... 2006 conference in San Francisco was witness to the ... of unhappy lumpectomy patients would explore the possibility of ...
Cached Medicine News:Health News:Novel Techniques to Tackle Colon Cancer 2Health News:Mental Health Package Regrettably Undervalues the Role of the GP 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: